DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth is attractive fundamentally because it is shifting from lower-visibility consumer revenue toward a higher-retention B2B2C model, with 1Q26 revenue of $5.6M, a $13M committed/late-stage ARR base, and a pipeline that expanded to $127M. Its differentiated moat comes from owning connected FDA-cleared devices, proprietary AI like DarioIQ, and coaching inside a vertically integrated platform, which is already producing 80%+ gross margins in B2B2C for a ninth consecutive quarter and should improve engagement and recurring revenue over time. The company also has clear operating leverage, with non-GAAP expenses down 17% y/y to a $34.8M run-rate, a target to reach roughly $31M by 4Q26, and management still pursuing cash-flow breakeven by mid-2027 while commercial wins with major health plans, employers, and hospital systems broaden access.

DarioHealth is facing a challenging digital health demand backdrop, with 2Q revenue of $5.2M missing estimates of $5.7M as both B2C and B2B underperformed, while adjusted EBITDA loss of ($5.3M) also missed expectations. Although gross margin was a solid 65% and management has $13M in new contracted ARR expected to begin contributing from 4Q and ramp through 2027, that pipeline does not offset near-term weakness in growth visibility. The negative outlook is driven by limited confidence in B2B2C and partnerships, churn risks, and the likelihood that continued cost-focused operations or future capital raises could remain dilutive and signal ongoing stress.